👉...cutting-edge science, clinical insights & discussions re: real-world implementation of TIL therapy.

Featuring keynote speakers:
Inge Marie Svane 🇩🇰 & Sebastian Klobuch 🇳🇱.

@sklobuch.bsky.social
@debrajosephs.bsky.social
@turajliclab.bsky.social
@beckilee.bsky.social

Thank you so much Sophia 😊

Beyond immune checkpoint blockade: what’s next for #melanoma?
At #ESMO25, explore:
📌 Why move beyond ICB
📌 #AdoptiveCellTherapy
📌 Treating unresectable stage IV melanoma
📌 Bispecific T-cell engagers
📅 17 Oct | 14:00–15:30

🔗 buff.ly/RaDTAFV

🚀 ESMO is now on Bluesky

This is not an April Fools' announcement, nor is it an AI-generated post. ESMO is launching on Bluesky with a poll on AI to start the conversation.

Join us for the latest in oncology education and information.

#AIOncology #HealthAI #ESMOAI25

🔗 https://www.esmoiotech.org/article/S2590-0188(24)00034-0/fulltext

📚 Our review on the management of toxicities of cell therapy for solid cancers is now out in print in #ESMO ‘s flagship IO journal ESMO IOTECH.

👉 incl. TILs, TCR-T & CAR-T + associated tx e.g. IL-2 & NMA-LD.

🔗 www.esmoiotech.org/article/S259...

@sophiawongyn.bsky.social
@fbmh-uom.bsky.social

Thank you Jon!

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial Nature Medicine - In this phase 1 trial of a personalized, neoantigen-specific autologous T cell therapy, BNT221, when given as monotherapy in patients with metastatic melanoma refractory to PD-1...

Just published: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
rdcu.be/d5ptS

Yes definitely. A first good resolution for 2025 👍

So sad that you are not here!

Let’s go! 🙌🏼🙌🏼🙌🏼
#CellTherapy
#TILTherapy

Welcome to 🦋🦋🦋
@drbetofmdphd.bsky.social
@sklobuch.bsky.social

Yay 🙌! Our #CellTherapy for solid cancers community is growing here 🦋.

Welcome 👋
@drbetofmdphd.bsky.social 🇺🇸
@sklobuch.bsky.social 🇳🇱
@sophiawongyn.bsky.social 🇸🇬

#CancerImmunotherapy